• Total Revenue: Increased by 23% year-over-year to $30.6 million.

• Medical Device Segment: Revenue up 24% with record product sales.

• GAAP Net Loss: Improved to $(0.8) million from $(7.8) million in the prior-year period.

• Adjusted EBITDA: Turned positive at $3.9 million, a significant improvement from the prior-year period.

• Product Gross Margin: Decreased to 53.2% from 63.0% due to sales mix and production inefficiencies.

• Operating Costs: Decreased by 18% year-over-year, reflecting lower R&D and SG&A expenses.

• Cash Position: Ended the quarter with $35.2 million in cash and investments.

• Warning! GuruFocus has detected 4 Warning Signs with SRDX.

On February 1, 2024, Surmodics Inc (NASDAQ:SRDX) released its 8-K filing, detailing financial results for the first quarter of fiscal year 2024, which ended on December 31, 2023. The company, a leading provider of medical device and in vitro diagnostic technologies, reported a significant year-over-year increase in total revenue and a substantial reduction in net loss, signaling a strong start to the fiscal year.

Surmodics Inc (NASDAQ:SRDX) operates in two primary segments: Medical Device, which focuses on performance coatings for a variety of medical devices, and In Vitro Diagnostics, which produces components for diagnostic tests and research. The majority of the company's revenue is derived from the Medical Device segment, which saw a notable increase in product sales, particularly from the vascular interventions portfolio.

Financial Performance Highlights

The company's revenue growth was driven by a 24% increase in the Medical Device segment, with product sales climbing by 43% year-over-year, largely due to the success of the SurVeil drug-coated balloon and Pounce thrombectomy products. The In Vitro Diagnostics segment also contributed to the growth, with an 18% increase in revenue.

Despite the positive revenue trends, the product gross margin experienced a decline from the previous year, attributed to the sales of newer products that have not yet achieved scale and the associated production inefficiencies. However, Surmodics Inc (NASDAQ:SRDX) managed to reduce operating costs significantly, primarily due to lower research and development expenses and the implementation of a spending reduction plan.

The company's balance sheet remains robust, with $35.2 million in cash and investments. However, there was an increase in total cash used, which amounted to $10.2 million for the quarter.

Operational and Strategic Developments

Surmodics Inc (NASDAQ:SRDX) highlighted several key operational achievements, including the launch of the Preside medical device coating technology and the presentation of positive clinical trial data for its SurVeil and Sundance drug-coated balloons. Additionally, the early clinical use of the Pounce LP Thrombectomy System was announced, addressing a critical need in thrombectomy procedures.